GlassScriptPhysician profile
Margaret A Libby
NPI 1235112822
$2,205.80
in general payments reported to CMS, 2019-2025
30 companies · $331 in 2025
The $331 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $231 · 2020: $40.70 · 2021: $171 · 2022: $417 · 2023: $781 · 2024: $234 · 2025: $331.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,346.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,345.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $318.49 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $247.56 | 2021-2025 | Otezla, Repatha, Otezla |
| Pfizer INC. | $209.07 | 2019-2024 | |
| Gilead Sciences, INC. | $158.25 | 2022-2023 | Epclusa |
| Mannkind Corporation | $155.58 | 2022-2023 | Afrezza |
| Insulet Corporation | $131.29 | 2023-2025 | Omnipod |
| Glaxosmithkline, LLC. | $102.36 | 2022-2023 | Trelegy Ellipta |
| Lilly USA, LLC | $100.62 | 2019-2025 | Mounjaro, Zepbound |
| Abbvie INC. | $92.16 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $74.49 | 2022-2023 | |
| Astellas Pharma US INC | $58.02 | 2023-2025 | Veozah |
| Dexcom, INC. | $55.01 | 2023-2024 | Dexcom G6 Transmitter |
| E.R. Squibb & Sons, L.L.C. | $52.38 | 2022-2023 | Eliquis |
| Otsuka America Pharmaceutical, INC. | $47.52 | 2022-2023 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $44.50 | 2022-2023 | Trintellix |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $41.40 | 2023-2025 | Freestyle Libre 3 |
| Baxter Healthcare | $40.29 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Merck Sharp & Dohme LLC | $39.30 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $37.41 | 2021-2023 | Austedo |
| Phathom Pharmaceuticals, INC. | $36.06 | 2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.74 | 2021 | |
| Amarin Pharma, INC. | $22.95 | 2022 | |
| Sobi, INC | $18.29 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.19 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.49 | 2022 | |
| Exact Sciences Corporation | $15.93 | 2025 | Cologuard Collection Kit |
| Alkermes, INC. | $13.15 | 2024 | Vivitrol |
| Smith+Nephew, INC. | $11.66 | 2019 | |
| Medtronic, INC. | $11.57 | 2021 | |
| Philips North America LLC | $11.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Margaret Libby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.